

OXIS International Announces the Launch of Oxis Consumer Products Subsidiary

BEVERLY HILLS, Calif., Aug. 31 -- **OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI)** announced today the launch of its wholly owned subsidiary, Oxis Consumer Products (OCP), focused on the development, marketing, promotion, and sales of direct to consumer brands. OCP will be responsible for sales, marketing and distribution of the recently announced *ErgoFlex®* and *ErgoPLex®* products as well as additional consumer products currently in development. In addition, OCP is currently in negotiation with several prestigious companies regarding formation of Joint Ventures in numerous consumer brand verticals. OXIS will continue to update its shareholders as these opportunities are completed.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. Please visit www.oxis.com for additional information.

Forward-Looking Statement

This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company's filings with the Securities and Exchange Commission.

SOURCE OXIS International, Inc.

CONTACT: Bruce Voss or Don Markley, Lippert/Heilshorn & Associates, +1-310-691-7100